BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16491126)

  • 1. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF.
    Wang P; Greiner TC; Lushnikova T; Eischen CM
    Oncogene; 2006 Jun; 25(26):3708-18. PubMed ID: 16491126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.
    Eischen CM; Boyd K
    PLoS One; 2012; 7(9):e46148. PubMed ID: 23029416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
    Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
    Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
    Lin AW; Lowe SW
    Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of neurofibromatosis-1 and p19(ARF) cooperate to induce a multiple tumor phenotype.
    King D; Yang G; Thompson MA; Hiebert SW
    Oncogene; 2002 Jul; 21(32):4978-82. PubMed ID: 12118376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2.
    Nitta RT; Smith CL; Kennedy BK
    PLoS One; 2007 Sep; 2(9):e963. PubMed ID: 17896003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis.
    Inoue K; Wen R; Rehg JE; Adachi M; Cleveland JL; Roussel MF; Sherr CJ
    Genes Dev; 2000 Jul; 14(14):1797-809. PubMed ID: 10898794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.
    Eischen CM; Rehg JE; Korsmeyer SJ; Cleveland JL
    Cancer Res; 2002 Apr; 62(7):2184-91. PubMed ID: 11929842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.
    O'Leary KA; Mendrysa SM; Vaccaro A; Perry ME
    Mol Cell Biol; 2004 Jan; 24(1):186-91. PubMed ID: 14673154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
    Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
    Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
    Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
    Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
    Tago K; Chiocca S; Sherr CJ
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
    Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
    Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor spectrum in ARF-deficient mice.
    Kamijo T; Bodner S; van de Kamp E; Randle DH; Sherr CJ
    Cancer Res; 1999 May; 59(9):2217-22. PubMed ID: 10232611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
    Zou X; Ray D; Aziyu A; Christov K; Boiko AD; Gudkov AV; Kiyokawa H
    Genes Dev; 2002 Nov; 16(22):2923-34. PubMed ID: 12435633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
    Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
    Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
    Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
    PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2.
    Chang DL; Qiu W; Ying H; Zhang Y; Chen CY; Xiao ZX
    Oncogene; 2007 Jul; 26(32):4627-34. PubMed ID: 17297463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.